TOVX
Theriva Biologics, Inc.
Price Chart
Latest Quote
$0.27
-0.01 (-2.74%)
Current Price
| Previous Close | $0.28 |
| Open | $0.28 |
| Day High | $0.28 |
| Day Low | $0.26 |
| Volume | 1,114,572 |
Stock Information
| Shares Outstanding | 45.89M |
| Total Debt | $3.69M |
| Cash Equivalents | $14.43M |
| Revenue | $300K |
| Net Income | $-22.97M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12.39M |
| EPS (TTM) | $-0.58 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.00M |
| Sales | $300K |
| Income | $-22.97M |
| Book/sh | $0.43 |
| Cash/sh | $0.31 |
| Employees | 15 |
Financial Ratios
| Quick Ratio | 1.58 |
| Current Ratio | 1.63 |
| Debt/Eq | 23.98 |
Returns & Margins
| ROA | -22.60% |
| ROE | -138.91% |
| Gross Margin | 100.00% |
| Operating Margin | -709.00% |
Ownership
| Insider Ownership | 1.70% |
| Institutional Ownership | 4.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.35 |
| P/S | 41.30 |
| P/B | 0.63 |
Analyst Data
| Recommendation | none |
| Target Price | $2.50 |
Technical Indicators
| SMA20 | $0.28 |
| SMA50 | $0.31 |
| SMA200 | $0.28 |
| RSI | 40.00 |
| ATR | 0.0393 |
| Shares Float | 45.14M |
| Short Float | 5.94% |
| Short Ratio | 1.12 |
| Volatility | 1.09 |
| Rel Volume | 0.07 |
Performance History
| Week | +12.50% |
| Month | -10.00% |
| Quarter | +50.00% |
| 6 Months | +35.00% |
| YTD | +3.85% |
| Year | -42.55% |
| 3 Years | -98.46% |
| 5 Years | -99.85% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $0.27 | 1,135,600 |
| 2026-06-16 | $0.28 | 1,746,700 |
| 2026-06-15 | $0.29 | 3,488,000 |
| 2026-06-12 | $0.30 | 7,639,900 |
| 2026-06-11 | $0.31 | 290,080,600 |
| 2026-06-10 | $0.24 | 1,020,000 |
| 2026-06-09 | $0.24 | 1,425,000 |
| 2026-06-08 | $0.26 | 1,035,100 |
| 2026-06-05 | $0.26 | 2,480,700 |
| 2026-06-04 | $0.28 | 890,100 |
| 2026-06-03 | $0.29 | 564,000 |
| 2026-06-02 | $0.29 | 1,073,300 |
| 2026-06-01 | $0.28 | 1,537,200 |
| 2026-05-29 | $0.28 | 1,698,000 |
| 2026-05-28 | $0.31 | 1,404,800 |
| 2026-05-27 | $0.29 | 1,001,900 |
| 2026-05-26 | $0.30 | 1,627,400 |
| 2026-05-22 | $0.31 | 1,298,900 |
| 2026-05-21 | $0.30 | 1,005,300 |
| 2026-05-20 | $0.30 | 3,103,100 |
| 2026-05-19 | $0.27 | 1,953,400 |
| 2026-05-18 | $0.30 | 1,540,100 |
About Theriva Biologics, Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral Ã-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $24,051,000 | $19,427,000 | $21,431,000 | $21,581,000 |
| Other Income Expense | $25,000 | $-6,923,000 | $3,000 | $-41,000 |
| Net Non Operating Interest Income Expense | $287,000 | $697,000 | $1,439,000 | $512,000 |
| Operating Expense | $24,051,000 | $19,427,000 | $21,431,000 | $21,581,000 |
| General And Administrative Expense | $15,447,000 | $7,396,000 | $7,120,000 | $9,858,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-23,739,000 | $-25,653,000 | $-18,349,000 | $-19,685,000 |
| Net Interest Income | $287,000 | $697,000 | $1,439,000 | $512,000 |
| Interest Income | $287,000 | $697,000 | $1,439,000 | $512,000 |
| Normalized Income | $-23,764,000 | $-18,730,000 | $-18,351,754 | $-19,646,768 |
| Net Income From Continuing And Discontinued Operation | $-23,739,000 | $-25,653,000 | $-18,349,000 | $-19,685,000 |
| Total Operating Income As Reported | $-24,051,000 | $-26,346,000 | $-21,431,000 | $-21,581,000 |
| Net Income Common Stockholders | $-25,249,000 | $-25,653,000 | $-18,349,000 | $-20,025,000 |
| Net Income | $-23,739,000 | $-25,653,000 | $-18,349,000 | $-19,685,000 |
| Net Income Including Noncontrolling Interests | $-23,739,000 | $-25,653,000 | $-18,349,000 | $-19,685,000 |
| Net Income Continuous Operations | $-23,739,000 | $-25,653,000 | $-18,349,000 | $-19,685,000 |
| Pretax Income | $-23,739,000 | $-25,653,000 | $-19,989,000 | $-21,110,000 |
| Special Income Charges | $0 | $-6,919,000 | $0 | - |
| Interest Income Non Operating | $287,000 | $697,000 | $1,439,000 | $512,000 |
| Operating Income | $-24,051,000 | $-19,427,000 | $-21,431,000 | $-21,581,000 |
| Per Share | ||||
| Diluted EPS | $-2.08 | $-19.03 | $-28.48 | $-32.75 |
| Basic EPS | $-2.08 | $-19.03 | $-28.48 | $-32.75 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $246 | $-2,768 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-23,968,000 | $-12,367,000 | $-21,299,000 | $-21,455,000 |
| Total Unusual Items | $25,000 | $-6,923,000 | $3,000 | $-41,000 |
| Total Unusual Items Excluding Goodwill | $25,000 | $-6,923,000 | $3,000 | $-41,000 |
| Reconciled Depreciation | $108,000 | $137,000 | $135,000 | $85,000 |
| EBITDA (Bullshit earnings) | $-23,943,000 | $-19,290,000 | $-21,296,000 | $-21,496,000 |
| EBIT | $-24,051,000 | $-19,427,000 | $-21,431,000 | $-21,581,000 |
| Diluted Average Shares | $12,140,697 | $1,348,126 | $644,282 | $613,093 |
| Basic Average Shares | $12,140,697 | $1,348,126 | $644,282 | $613,093 |
| Diluted NI Availto Com Stockholders | $-25,249,000 | $-25,653,000 | $-18,349,000 | $-20,025,000 |
| Otherunder Preferred Stock Dividend | $1,510,000 | $0 | $0 | $340,000 |
| Tax Provision | $0 | $0 | $-1,640,000 | $-1,425,000 |
| Write Off | $0 | $1,325,000 | $0 | - |
| Impairment Of Capital Assets | $0 | $5,594,000 | $0 | - |
| Gain On Sale Of Security | $25,000 | $-4,000 | $3,000 | $-41,000 |
| Research And Development | $8,604,000 | $12,031,000 | $14,311,000 | $11,723,000 |
| Selling General And Administration | $15,447,000 | $7,396,000 | $7,120,000 | $9,858,000 |
| Other Gand A | $15,447,000 | $7,396,000 | $7,120,000 | $9,858,000 |
| Minority Interests | - | - | - | $0 |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,236,000 | $1,709,000 | $14,242,000 | $29,889,000 |
| Total Assets | $38,239,000 | $35,352,000 | $55,219,000 | $71,861,000 |
| Total Non Current Assets | $20,772,000 | $19,071,000 | $27,816,000 | $26,341,000 |
| Other Non Current Assets | $128,000 | $171,000 | $180,000 | $122,000 |
| Goodwill And Other Intangible Assets | $19,619,000 | $17,358,000 | $25,455,000 | $24,675,000 |
| Other Intangible Assets | $19,619,000 | $17,358,000 | $19,755,000 | $19,150,000 |
| Current Assets | $17,467,000 | $16,281,000 | $27,403,000 | $45,520,000 |
| Prepaid Assets | $576,000 | $1,349,000 | $2,286,000 | $3,503,000 |
| Receivables | $3,835,000 | $3,323,000 | $1,940,000 | $231,000 |
| Other Receivables | $452,000 | - | - | $144,000 |
| Taxes Receivable | $3,383,000 | $3,323,000 | $1,940,000 | $87,000 |
| Cash Cash Equivalents And Short Term Investments | $13,056,000 | $11,609,000 | $23,177,000 | $41,786,000 |
| Cash And Cash Equivalents | $13,056,000 | $11,609,000 | $23,177,000 | $41,786,000 |
| Non Current Prepaid Assets | - | - | - | $23,000 |
| Debt | ||||
| Total Debt | $2,629,000 | $1,565,000 | $2,154,000 | $1,681,000 |
| Long Term Debt And Capital Lease Obligation | $2,023,000 | $965,000 | $1,604,000 | $1,408,000 |
| Long Term Debt | $1,671,000 | $92,000 | $162,000 | $221,000 |
| Current Debt And Capital Lease Obligation | $606,000 | $600,000 | $550,000 | $273,000 |
| Current Debt | $57,000 | $61,000 | $63,000 | $57,000 |
| Other Current Borrowings | $57,000 | $61,000 | $63,000 | $57,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,856,000 | $16,285,000 | $15,522,000 | $17,297,000 |
| Total Non Current Liabilities Net Minority Interest | $12,842,000 | $8,700,000 | $8,784,000 | $10,237,000 |
| Other Non Current Liabilities | $10,004,000 | $6,973,000 | $6,274,000 | $7,211,000 |
| Non Current Deferred Liabilities | $815,000 | $762,000 | $906,000 | $1,618,000 |
| Non Current Deferred Taxes Liabilities | $815,000 | $762,000 | $906,000 | $1,618,000 |
| Current Liabilities | $10,014,000 | $7,585,000 | $6,738,000 | $7,060,000 |
| Current Deferred Liabilities | $1,675,000 | $1,614,000 | $906,000 | $0 |
| Current Deferred Taxes Liabilities | $1,675,000 | $1,614,000 | $906,000 | $0 |
| Payables And Accrued Expenses | $7,580,000 | $5,184,000 | $5,155,000 | $3,727,000 |
| Payables | $1,014,000 | $859,000 | $770,000 | $915,000 |
| Accounts Payable | $1,014,000 | $859,000 | $770,000 | $915,000 |
| Other Current Liabilities | - | - | - | $2,973,000 |
| Equity | ||||
| Common Stock Equity | $15,383,000 | $19,067,000 | $36,963,000 | $51,830,000 |
| Total Equity Gross Minority Interest | $15,383,000 | $19,067,000 | $39,697,000 | $54,564,000 |
| Stockholders Equity | $15,383,000 | $19,067,000 | $39,697,000 | $54,564,000 |
| Gains Losses Not Affecting Retained Earnings | $755,000 | $-1,178,000 | $32,000 | $-679,000 |
| Other Equity Adjustments | $755,000 | $-1,178,000 | $32,000 | $-679,000 |
| Retained Earnings | $-358,710,000 | $-334,971,000 | $-309,318,000 | $-290,969,000 |
| Preferred Stock Equity | - | - | $2,734,000 | $2,734,000 |
| Other | ||||
| Treasury Shares Number | $28,809 | $28,809 | $28,809 | $28,800 |
| Ordinary Shares Number | $35,688,350 | $2,782,449 | $685,921 | $604,962 |
| Share Issued | $35,717,159 | $2,811,258 | $714,730 | $633,762 |
| Tangible Book Value | $-4,236,000 | $1,709,000 | $11,508,000 | $27,155,000 |
| Invested Capital | $17,111,000 | $19,220,000 | $37,188,000 | $52,108,000 |
| Working Capital | $7,453,000 | $8,696,000 | $20,665,000 | $38,460,000 |
| Capital Lease Obligations | $901,000 | $1,412,000 | $1,929,000 | $1,403,000 |
| Total Capitalization | $17,054,000 | $19,159,000 | $39,859,000 | $54,785,000 |
| Treasury Stock | $288,000 | $288,000 | $288,000 | $288,000 |
| Additional Paid In Capital | $373,592,000 | $355,501,000 | $346,536,000 | $343,750,000 |
| Capital Stock | $34,000 | $3,000 | $2,735,000 | $2,750,000 |
| Common Stock | $34,000 | $3,000 | $1,000 | $16,000 |
| Long Term Capital Lease Obligation | $352,000 | $873,000 | $1,442,000 | $1,187,000 |
| Current Capital Lease Obligation | $549,000 | $539,000 | $487,000 | $216,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $153,000 | $187,000 | $127,000 | $87,000 |
| Current Accrued Expenses | $6,566,000 | $4,325,000 | $4,385,000 | $2,812,000 |
| Net PPE | $1,025,000 | $1,542,000 | $2,181,000 | $1,544,000 |
| Accumulated Depreciation | $-966,000 | $-935,000 | $-1,002,000 | $-865,000 |
| Gross PPE | $1,991,000 | $2,477,000 | $3,183,000 | $2,409,000 |
| Leases | $94,000 | $94,000 | $94,000 | $94,000 |
| Other Properties | $1,247,000 | $1,664,000 | $2,176,000 | $1,407,000 |
| Machinery Furniture Equipment | $650,000 | $719,000 | $913,000 | $908,000 |
| Properties | $0 | $0 | $0 | $0 |
| Preferred Stock | - | $0 | $2,734,000 | $2,734,000 |
| Goodwill | - | $0 | $5,700,000 | $5,525,000 |
| Minority Interest | - | - | - | - |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,704,000 | $-16,938,000 | $-19,198,000 | $-19,198,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,669,000 | $-16,937,000 | $-18,996,000 | $-19,082,000 |
| Cash Flow From Continuing Operating Activities | $-16,669,000 | $-16,937,000 | $-18,996,000 | $-19,082,000 |
| Operating Gains Losses | $1,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-35,000 | $-1,000 | $-202,000 | $-116,000 |
| Investing Cash Flow | $-35,000 | $-1,000 | $-202,000 | $-4,396,000 |
| Cash Flow From Continuing Investing Activities | $-35,000 | $-1,000 | $-202,000 | $-4,396,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $13,523,000 | $5,563,000 | $2,219,000 | $2,734,000 |
| Financing Cash Flow | $18,193,000 | $5,496,000 | $625,000 | $-1,930,000 |
| Cash Flow From Continuing Financing Activities | $18,193,000 | $5,496,000 | $625,000 | $-1,930,000 |
| Net Other Financing Charges | $-713,000 | - | $-1,519,000 | $-3,000,000 |
| Net Common Stock Issuance | $13,523,000 | $5,563,000 | $2,219,000 | $-288,000 |
| Common Stock Issuance | $13,523,000 | $5,563,000 | $2,219,000 | $0 |
| Repurchase Of Capital Stock | - | - | $0 | $-288,000 |
| Net Preferred Stock Issuance | - | - | $0 | $2,734,000 |
| Preferred Stock Issuance | - | - | $0 | $2,734,000 |
| Other | ||||
| Repayment Of Debt | $-70,000 | $-67,000 | $-75,000 | $-1,376,000 |
| Issuance Of Debt | $1,507,000 | $0 | - | - |
| End Cash Position | $13,102,000 | $11,705,000 | $23,279,000 | $41,885,000 |
| Beginning Cash Position | $11,705,000 | $23,279,000 | $41,885,000 | $67,325,000 |
| Effect Of Exchange Rate Changes | $-92,000 | $-132,000 | $-33,000 | $-32,000 |
| Changes In Cash | $1,489,000 | $-11,442,000 | $-18,573,000 | $-25,408,000 |
| Proceeds From Stock Option Exercised | $3,946,000 | $0 | - | $0 |
| Net Issuance Payments Of Debt | $1,437,000 | $-67,000 | $-75,000 | $-1,376,000 |
| Net Long Term Debt Issuance | $1,437,000 | $-67,000 | $-75,000 | $-1,376,000 |
| Long Term Debt Payments | $-70,000 | $-67,000 | $-75,000 | $-1,376,000 |
| Long Term Debt Issuance | $1,507,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-35,000 | $-1,000 | $-202,000 | $-116,000 |
| Purchase Of PPE | $-35,000 | $-1,000 | $-202,000 | $-116,000 |
| Change In Working Capital | $-3,058,000 | $726,000 | $2,309,000 | $-806,000 |
| Change In Other Current Liabilities | $-562,000 | $-482,000 | $-422,000 | $-124,000 |
| Change In Payables And Accrued Expense | $-2,952,000 | $295,000 | $1,417,000 | $-319,000 |
| Change In Accrued Expense | $-3,021,000 | $172,000 | $1,574,000 | $66,000 |
| Change In Payable | $69,000 | $123,000 | $-157,000 | $-385,000 |
| Change In Account Payable | $69,000 | $123,000 | $-157,000 | $-385,000 |
| Change In Prepaid Assets | $456,000 | $913,000 | $1,314,000 | $-363,000 |
| Other Non Cash Items | $9,553,000 | $1,151,000 | $-2,003,000 | $2,274,000 |
| Stock Based Compensation | $654,000 | $671,000 | $552,000 | $475,000 |
| Asset Impairment Charge | $0 | $6,919,000 | $0 | - |
| Deferred Tax | $-188,000 | $-888,000 | $-1,640,000 | $-1,425,000 |
| Deferred Income Tax | $-188,000 | $-888,000 | $-1,640,000 | $-1,425,000 |
| Depreciation Amortization Depletion | $108,000 | $137,000 | $135,000 | $85,000 |
| Depreciation And Amortization | $108,000 | $137,000 | $135,000 | $85,000 |
| Depreciation | $108,000 | $137,000 | $135,000 | $85,000 |
| Net Income From Continuing Operations | $-23,739,000 | $-25,653,000 | $-18,349,000 | $-19,685,000 |
| Common Stock Payments | - | - | $0 | $-288,000 |
| Net Business Purchase And Sale | - | - | $0 | $-4,280,000 |
| Purchase Of Business | - | - | $0 | $-4,280,000 |
| Change In Other Working Capital | - | - | - | $333,000 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-06-15